The introduction of nicotinamide for a nicotine substitution in e-cigarette and smokeless products and solutions signifies a significant regulatory challenge for the FDA. Nicotinamide doesn't have nicotinic receptor agonist activity and is understood to act as a sedative at large dosages6. The claims produced by Nicotine River, ECBlend, and also ot